Transplant outcomes after intermediate intensity dCBT. (A) Cumulative incidence of neutrophil engraftment in patients who received dCB grafts only (n = 47). Patients who received dCB grafts combined with haplo-identical CD34⁺ cells were excluded because of transient haploidentical donor-derived myeloid bridging before sustained CB engraftment. (B) Cumulative incidence of acute GVHD by 180 days after transplant (n = 90). (C) Three-year cumulative incidence of chronic GVHD (n = 90). (D) Three-year cumulative incidence of TRM (n = 90). (E) Three-year cumulative incidence of relapse (n = 90). (F) Loess-smoothed averages of lymphocyte subset recovery including CD4⁺-, CD8⁺-, NK-, and B-cell subsets. As there were no differences in recovery after dCBT and dCBT combined with haplo-identical cells, these patients were combined (n = 90).